155 related articles for article (PubMed ID: 15297187)
1. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray.
Dupont J; Wang X; Marshall DS; Leitao M; Hedvat CV; Hummer A; Thaler H; O'Reilly RJ; Soslow RA
Gynecol Oncol; 2004 Aug; 94(2):449-55. PubMed ID: 15297187
[TBL] [Abstract][Full Text] [Related]
2. Wilms' tumor gene 1 (WT1) in endometrial carcinoma.
Coosemans A; Moerman P; Verbist G; Maes W; Neven P; Vergote I; Van Gool SW; Amant F
Gynecol Oncol; 2008 Dec; 111(3):502-8. PubMed ID: 18929401
[TBL] [Abstract][Full Text] [Related]
3. The significance of Wilms Tumor Gene (WT1) and p53 expression in curettage specimens of patients with endometrial carcinomas.
Matalka I; Obeidat B; Mohtaseb A; Awamleh A
Pathol Res Pract; 2013 Jan; 209(1):19-23. PubMed ID: 23207289
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of WT1 protein in endometrial cancer.
Ohno S; Dohi S; Ohno Y; Kyo S; Sugiyama H; Suzuki N; Inoue M
Anticancer Res; 2009 May; 29(5):1691-5. PubMed ID: 19443388
[TBL] [Abstract][Full Text] [Related]
5. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Christensen IJ; Gayther S; Jacobs IJ; Høgdall CK
Gynecol Oncol; 2007 Aug; 106(2):318-24. PubMed ID: 17540436
[TBL] [Abstract][Full Text] [Related]
6. p53 as a prognostic indicator in endometrial cancer.
Geisler JP; Wiemann MC; Zhou Z; Miller GA; Geisler HE
Gynecol Oncol; 1996 May; 61(2):245-8. PubMed ID: 8626141
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
8. Correlation between WT1 expression and cell proliferation in endometrial cancer.
Dohi S; Ohno S; Ohno Y; Soma G; Kyo S; Inoue M
Anticancer Res; 2009 Nov; 29(11):4887-91. PubMed ID: 20032452
[TBL] [Abstract][Full Text] [Related]
9. Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer.
Hylander B; Repasky E; Shrikant P; Intengan M; Beck A; Driscoll D; Singhal P; Lele S; Odunsi K
Gynecol Oncol; 2006 Apr; 101(1):12-7. PubMed ID: 16263157
[TBL] [Abstract][Full Text] [Related]
10. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Giordano G; Gnetti L; Merisio C; Melpignano M
Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium.
Egan JA; Ionescu MC; Eapen E; Jones JG; Marshall DS
Int J Gynecol Pathol; 2004 Apr; 23(2):119-22. PubMed ID: 15084839
[TBL] [Abstract][Full Text] [Related]
12. The association between p53 expression, stage and histological features in endometrial cancer.
Ragni N; Ferrero S; Prefumo F; Muschiato B; Gorlero F; Gualco M; Fulcheri E
Eur J Obstet Gynecol Reprod Biol; 2005 Nov; 123(1):111-6. PubMed ID: 15894417
[TBL] [Abstract][Full Text] [Related]
13. Fluorescence in situ hybridization and immunohistochemical analysis of p53 expression in endometrial cancer: prognostic value and relation to ploidy.
Graesslin O; Chantot-Bastaraud S; Lorenzato M; Birembaut P; Quéreux C; Daraï E
Ann Surg Oncol; 2008 Feb; 15(2):484-92. PubMed ID: 18071824
[TBL] [Abstract][Full Text] [Related]
14. WT1 immunoprofiling and comparison of malignant Mullerian mixed tumors of the female genital tract.
Franko A; Magliocco AM; Duan Q; Duggan MA
Int J Gynecol Pathol; 2010 Sep; 29(5):452-8. PubMed ID: 20736771
[TBL] [Abstract][Full Text] [Related]
15. A role of thymidine phosphorylase and P53 tissue protein expression in biology of endometrial cancer.
Mazurek A; Kuć P; Mazurek-Wadołkowska E; Laudański T
Neoplasma; 2008; 55(3):261-5. PubMed ID: 18348659
[TBL] [Abstract][Full Text] [Related]
16. Loss of Fhit protein expression in high-grade and advanced stage endometrial carcinomas.
Yura Y; Mandai M; Konishi I; Hamid AA; Tsuruta Y; Kusakari T; Fujii S
Anticancer Res; 2003; 23(3C):2837-43. PubMed ID: 12926121
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of angiogenesis, p-53 tissue protein expression and serum VEGF in patients with endometrial cancer.
Mazurek A; Pierzyński P; Kuć P; Kopinski P; Terlikowski S; Niklińska W; Trojan J; Laudański T
Neoplasma; 2004; 51(3):193-7. PubMed ID: 15254672
[TBL] [Abstract][Full Text] [Related]
18. BCL-2, BAX and P53 expression profiles in endometrial carcinoma as studied by real-time PCR and immunohistochemistry.
Porichi O; Nikolaidou ME; Apostolaki A; Tserkezoglou A; Arnogiannaki N; Kassanos D; Margaritis L; Panotopoulou E
Anticancer Res; 2009 Oct; 29(10):3977-82. PubMed ID: 19846939
[TBL] [Abstract][Full Text] [Related]
19. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.
Morrison C; Zanagnolo V; Ramirez N; Cohn DE; Kelbick N; Copeland L; Maxwell GL; Fowler JM
J Clin Oncol; 2006 May; 24(15):2376-85. PubMed ID: 16710036
[TBL] [Abstract][Full Text] [Related]
20. BCL-2 and P53 expression in endometrial carcinoma.
Erkanli S; Eren F; Pekin S; Bagis T
J Exp Clin Cancer Res; 2004 Mar; 23(1):97-103. PubMed ID: 15149157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
